Sponsor Oversight of CROs and Vendors: What ICH E6(R3) Means in Practice

Modern clinical trials are rarely delivered by the sponsor alone.

A single development programme may involve:

• A global CRO
• Regional or local CROs
• Central laboratories
• Imaging providers
• EDC and eClinical vendors
• Pharmacovigilance providers
• Biostatistics teams
• Medical writers
• Translation vendors
• Logistics providers
• Home-health providers
• Recruitment vendors

Outsourcing enables sponsors to access specialist expertise, infrastructure and geographic reach.

But it creates another challenge:

How does a sponsor maintain appropriate control and visibility over activities performed by other organizations?

This is the essence of sponsor oversight.

And under modern Good Clinical Practice, outsourcing does not mean transferring away ultimate sponsor responsibility.

ICH E6(R3) states that sponsors may transfer trial-related activities to service providers, but the ultimate responsibility for those sponsor activities—including participant rights, safety and well-being and reliability of trial data—remains with the sponsor.

That principle has major practical implications.

Delegation Is Not Abdication

Consider a sponsor that outsources monitoring to a CRO.

The CRO selects and manages CRAs.

The CRAs monitor the sites.

Does that mean the sponsor no longer needs visibility into monitoring?

No.

The sponsor needs sufficient oversight to understand whether the transferred activity is being performed appropriately.

The same principle applies when outsourcing:

Pharmacovigilance

Data management

Biostatistics

Medical writing

Laboratory services

Technology

Regulatory operations

The sponsor does not need to duplicate every vendor activity.

But it does need an operating model that provides appropriate assurance.

What Does ICH E6(R3) Actually Expect?

E6(R3) strengthens and modernizes the concept of sponsor oversight.

The FDA's final E6(R3) guidance states that the sponsor is responsible for assessing the suitability and selecting service providers, should have access to relevant information such as SOPs and performance metrics for selection and oversight, and should appropriately oversee important transferred activities—including activities further subcontracted by the service provider.

This gives sponsors several practical responsibilities:

Select appropriately.

Define responsibilities clearly.

Maintain access to relevant information.

Monitor important activities.

Understand subcontracting.

Act when performance creates risk.

Oversight therefore begins before the contract is signed.

Step 1: Select the Right Provider

Vendor oversight starts with vendor selection.

Before appointing a CRO or specialist provider, sponsors should understand whether the organization is capable of performing the intended activities.

Depending on the service, assessment may include:

• Relevant therapeutic-area experience
• Geographic capability
• Staff qualifications
• Quality systems
• SOPs
• Technology
• Information security
• Regulatory experience
• Inspection history
• Business continuity
• Subcontracting model
• Capacity
• Financial/organizational stability

The objective is not to find a vendor that looks impressive during a bid defence.

It is to determine whether the organization can actually deliver the required scope within the context of the trial.

Step 2: Define Responsibilities Before Work Begins

One of the most preventable causes of operational failure is unclear ownership.

Consider an SAE.

Who follows up with the site?

The CRA?

PV vendor?

Medical monitor?

Sponsor?

What about a protocol deviation?

Who assesses significance?

Who escalates it?

Who documents the decision?

If the answer is:

“It depends who notices first,”

the governance model is not sufficiently defined.

Sponsors should document responsibilities through appropriate agreements, plans and responsibility matrices.

For complex programmes, a RACI can help define who is:

Responsible

Accountable

Consulted

Informed

The exact tool matters less than the clarity it creates.

Step 3: Understand Subcontracting

A sponsor contracts with CRO A.

CRO A then subcontracts:

• Local monitoring to CRO B
• Translation to Vendor C
• Data services to Vendor D

Who oversees those activities?

This is increasingly important in global development.

ICH E6(R3) specifically states that sponsor oversight of important transferred trial-related activities should include activities further subcontracted by service providers.

Sponsors therefore need visibility into important subcontracting arrangements.

The organization performing the work may be several contractual layers away from the sponsor.

The risk is still connected to the sponsor's trial.

Step 4: Oversight Should Be Risk-Based

Effective oversight does not mean monitoring every vendor with equal intensity.

A company providing non-critical formatting support does not necessarily require the same governance as the organization responsible for:

• Clinical monitoring
• Safety reporting
• Primary endpoint assessment
• Randomization
• Clinical database management

Oversight should therefore consider:

Importance of the activity

Impact on participant safety

Impact on critical data

Complexity

Vendor experience

Performance history

Degree of subcontracting

This aligns with E6(R3)'s broader emphasis on proportionate and risk-based quality management. EMA notes that the revised guideline promotes quality by design, critical-to-quality thinking and proportionate risk-based approaches.

Step 5: Define Meaningful Performance Indicators

A governance meeting is not effective oversight simply because it occurs every month.

Sponsors need information capable of revealing whether the study is functioning appropriately.

Depending on the vendor, useful indicators might include:

Clinical Operations

• Site activation timelines
• Monitoring visit completion
• Monitoring report finalization
• Protocol deviation trends
• Action-item aging

Data Management

• Query aging
• Data-entry lag
• Missing critical data
• Reconciliation status

Pharmacovigilance

• SAE processing timeliness
• Follow-up status
• Regulatory submission compliance
• Reconciliation discrepancies

TMF

• Document completeness
• Filing timeliness
• QC findings
• Missing critical documents

The objective is not to generate the largest possible dashboard.

It is to identify metrics that tell the sponsor whether important activities remain under control.

Step 6: Metrics Need Interpretation

Imagine the CRO reports:

98% of monitoring visits completed on time.

That sounds excellent.

But what if:

• Important findings remain unresolved?
• Reports are consistently late?
• Eligibility deviations are increasing?
• SAE reporting issues are recurring?

One KPI rarely tells the whole story.

Oversight requires context and trend interpretation.

Sponsors should ask:

“What does this metric tell us about risk?”

rather than simply:

“Is it green?”

A dashboard full of green indicators can still conceal an important problem if the wrong things are being measured.

Step 7: Governance Needs Decision Rights

Governance meetings should not become status-reading exercises.

They should support decisions.

A useful governance structure defines:

What can the vendor resolve independently?

What requires sponsor approval?

What must be escalated immediately?

Who makes the final decision?

How is the decision documented?

For example:

Routine operational scheduling → CRO management.

Repeated minor site deviations → CRO investigation with sponsor visibility.

Potential serious breach or participant-safety concern → immediate escalation.

Major protocol interpretation → sponsor/medical governance.

Clear decision rights create both speed and accountability.

Step 8: Oversight Is Not Micromanagement

This distinction is critical.

A sponsor does not demonstrate oversight by:

• Re-performing every CRO task
• Reviewing every email
• Attending every site call
• Duplicating every QC step

That creates inefficiency and blurs accountability.

The CRO should be allowed to perform the activities it was contracted to perform.

Sponsor oversight should instead provide confidence that:

Responsibilities are clear.

Performance is visible.

Important risks are identified.

Problems are escalated.

Corrective actions are effective.

Critical decisions remain appropriately controlled.

Good oversight is visibility plus governance, not duplication.

Step 9: Problems Should Become Visible Early

One of the strongest indicators of an effective sponsor-CRO relationship is whether bad news travels quickly.

If a vendor waits until a governance meeting to disclose:

• Significant recruitment failure
• Repeated critical deviations
• Safety-reporting problems
• Major data-quality issues

the oversight system is reactive.

Escalation expectations should be defined before the study begins.

Teams should know:

What constitutes an escalation?

Who receives it?

How quickly?

What happens next?

A mature quality culture rewards early visibility rather than encouraging teams to keep problems hidden until they can present a solution.

Step 10: Sponsor Oversight Must Extend to Systems and Data

Vendors may host critical systems:

EDC

CTMS

eTMF

RTSM/IRT

Safety databases

eCOA

Sponsors need sufficient understanding of how these systems support the trial and how important risks are controlled.

Depending on context, this may include:

• System suitability
• Validation
• Access controls
• Data transfers
• Audit trails
• Change control
• Security
• Backup
• Business continuity

E6(R3) explicitly integrates computerized systems and data governance into modern GCP, reflecting how central technology has become to clinical-trial quality.

Step 11: Inspect the Interfaces

Some of the highest risks in outsourced trials exist between organizations.

Consider:

Site → CRO

CRO → Safety Vendor

Safety Vendor → Sponsor

Central Lab → Data Management

Data Management → Statistics

Each interface creates opportunities for:

• Delayed information
• Duplicate work
• Missing information
• Inconsistent data
• Unclear ownership

Vendor oversight should therefore examine not only whether each organization performs its own task-but whether the handoffs between them work.

A perfect process inside Vendor A is not enough if critical information fails to reach Vendor B.

Step 12: Document Oversight

If oversight occurs but cannot be reconstructed, it becomes difficult to demonstrate.

Appropriate documentation may include:

• Governance minutes
• Performance dashboards
• Risk reviews
• Escalation records
• Decision logs
• CAPA follow-up
• Vendor assessments
• Quality documentation

The goal is not documentation for documentation's sake.

The record should show:

What did the sponsor know, what did it decide, and what did it do?

Step 13: Oversight Should Change When Risk Changes

Vendor oversight should not remain static throughout a study.

Suppose a CRO begins with strong performance.

Later:

• Key staff leave
• Monitoring reports become delayed
• Site issues accumulate
• Recruitment falls
• Data queries increase

The sponsor's oversight intensity may need to change.

Similarly, if a provider consistently demonstrates strong performance, some oversight activities may appropriately become less intensive.

This is risk-based governance in practice.

A Practical Sponsor Oversight Model

A strong framework can be summarized as:

QUALIFY

Is this the right provider?

↓

DEFINE

Who owns each activity?

↓

CONTRACT

Are responsibilities and expectations clear?

↓

MEASURE

What indicators demonstrate performance?

↓

REVIEW

What do the metrics and trends mean?

↓

ESCALATE

What happens when risk increases?

↓

ACT

Who owns remediation?

↓

VERIFY

Did the corrective action work?

↓

DOCUMENT

Can oversight and decisions be reconstructed?

This cycle continues throughout the trial.

Five Questions Sponsor Leadership Should Ask

At any point in an outsourced clinical trial, leadership should be able to answer:

1. Which critical trial activities have we transferred?

2. Who is actually performing them-including subcontractors?

3. How do we know those activities are being performed appropriately?

4. What are our most important current vendor-related risks?

5. What happens when vendor performance deteriorates?

If those questions cannot be answered clearly, outsourcing may be functioning operationally-but sponsor oversight may not be.

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we believe effective outsourcing should create access to expertise without creating distance from accountability.

Sponsors should not need to reproduce every CRO activity.

But they do need:

Visibility

Clear responsibilities

Meaningful metrics

Risk-based governance

Effective escalation

Documented decisions

And CROs and specialist partners need enough operational authority to deliver efficiently within that framework.

The strongest sponsor-CRO relationship is therefore neither:

“Sponsor controls everything.”

nor

“CRO handles everything.”

It is:

“Responsibilities are clear, execution is delegated appropriately, performance is transparent and accountability remains visible.”

Because successful outsourcing is not measured by how much work has been transferred.

It is measured by whether the sponsor can remain confident that the trial is protecting participants and generating evidence that can be trusted.

References

1. International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice. Final Guideline. 2025.
2. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice: Guidance for Industry. Final Guidance. September 2025.
3. European Medicines Agency. ICH E6 Good Clinical Practice – Scientific Guideline. Current 2026.
4. International Council for Harmonisation. ICH E8(R1): General Considerations for Clinical Studies. 2021.